"I've felt so much better since we lowered my dose." ~ Vineyard Member GLP-1s change how your body experiences hunger, fullness, and energy, but not what your body needs
The neurogenetic syndrome associated with ADNP mutation, HVDAS, accounts for 0.17% of ASD cases and is therefore considered a high-risk gene [292]
This has been shown in mice and now Amgen has claimed they have shown it in humans (and have also claimed that the weight loss with this agonist/inhibitor drug is more sustained than the weight loss of agonist/agonist drug, but thats a separate issue I will cover in a later blog post)
4.3 AI-Driven Tools for Diagnosis and Management of DPN AI-driven tools are revolutionizing the diagnosis of DPN by enhancing accuracy, enabling early detection, and streamlining clinical workflows
It helps them fight off invaders without burning themselves out from their own "friendly fire" oxidative stress